RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Canada Opens Consultation on New Prescription Drug List

Canada Opens Consultation on New Prescription Drug List

Posted 02 January 2013 | By Louise Zornoza

Health Canada has opened a consultation regarding the new Prescription Drug List that is scheduled replace the existing Schedule F of the Food and Drug Regulations. The regulatory process to add or remove a drug from Schedule F will be replaced by an administrative process, requiring the amendment of all existing regulations and draft regulations that have been developed. 

Health Canada has also prepared a draft guidance document that explains the principles and factors that the agency will consider when deciding whether a drug would best be sold as a prescription drug or a non-prescription product. A proposed Prescription Drug List provides a user-friendly format for human use and for veterinary use, but does not include ingredients listed in the Controlled Drugs and Substances Act Schedules.

A question-and-answer document has also been released to assist the public in understanding the changes mandated by the Jobs, Growth and Long-term Prosperity Act (Bill C-38), which received Royal Assent on June 29, 2012.  The deadline for comments is 7 March 2013.


Read more:

Read all Breaking News from RegLink

 

© 2022 Regulatory Affairs Professionals Society.